Nice link.
As for the label, RLYP did in vitro drug-drug interaction (DDI) and found Veltassa interacted. The FDA then issued guidance for other compounds to test this effect, which includes ZS-9.
Unless ZS-9 has been tested in vitro and potentially in vivo, this compound will also get the same label as Veltassa. A second factor for ZS-9 is the salt content, which will restrict use in some patients. JMO
News 
Market Data 
Discover 
